CY1124685T1 - Εξατομικευμενα εμβολια για τον καρκινο - Google Patents
Εξατομικευμενα εμβολια για τον καρκινοInfo
- Publication number
- CY1124685T1 CY1124685T1 CY20211100945T CY211100945T CY1124685T1 CY 1124685 T1 CY1124685 T1 CY 1124685T1 CY 20211100945 T CY20211100945 T CY 20211100945T CY 211100945 T CY211100945 T CY 211100945T CY 1124685 T1 CY1124685 T1 CY 1124685T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- tumor
- patient
- relates
- present
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title abstract 2
- 238000009566 cancer vaccine Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 201000011510 cancer Diseases 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 206010069754 Acquired gene mutation Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000037439 somatic mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Ecology (AREA)
- Pathology (AREA)
- Physiology (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται στην παροχή εμβολίων που είναι ειδικά για τον όγκο ενός ασθενούς και είναι δυνητικά χρήσιμα για ανοσοθεραπεία του πρωτοπαθούς όγκου καθώς και μεταστάσεις όγκου. Από μία άποψη, η παρούσα εφεύρεση σχετίζεται με μια μέθοδο παροχής εξατομικευμένου εμβολίου κατά του καρκίνου που περιλαμβάνει τα βήματα: (α) αναγνώριση σωματικών μεταλλάξεων για καρκίνο σε δείγμα όγκου καρκινοπαθούς για την παροχή υπογραφής μετάλλαξης καρκίνου του ασθενούς• και (β) παροχή εμβολίου με την υπογραφή της μετάλλαξης του καρκίνου που λαμβάνεται στο βήμα (α). Σε μια περαιτέρω άποψη, η παρούσα εφεύρεση αναφέρεται σε εμβόλια, τα οποία μπορούν να ληφθούν με την εν λόγω μέθοδο.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/002576 WO2012159643A1 (en) | 2011-05-24 | 2011-05-24 | Individualized vaccines for cancer |
EP2012000006 | 2012-01-02 | ||
PCT/EP2012/002209 WO2012159754A2 (en) | 2011-05-24 | 2012-05-23 | Individualized vaccines for cancer |
EP12723117.3A EP2714071B1 (en) | 2011-05-24 | 2012-05-23 | Individualized vaccines for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124685T1 true CY1124685T1 (el) | 2022-07-22 |
Family
ID=50185364
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100986T CY1122110T1 (el) | 2011-05-24 | 2019-09-18 | Εξατομικευμενα εμβολια για τον καρκινο |
CY20211100945T CY1124685T1 (el) | 2011-05-24 | 2021-11-02 | Εξατομικευμενα εμβολια για τον καρκινο |
CY20231100248T CY1126128T1 (el) | 2011-05-24 | 2023-05-25 | Εξατομικευμενα εμβολια για τον καρκινο |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100986T CY1122110T1 (el) | 2011-05-24 | 2019-09-18 | Εξατομικευμενα εμβολια για τον καρκινο |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20231100248T CY1126128T1 (el) | 2011-05-24 | 2023-05-25 | Εξατομικευμενα εμβολια για τον καρκινο |
Country Status (8)
Country | Link |
---|---|
EP (4) | EP3473267B1 (el) |
CY (3) | CY1122110T1 (el) |
DK (1) | DK3473267T3 (el) |
HR (1) | HRP20191535T1 (el) |
ME (1) | ME03498B (el) |
PL (2) | PL3473267T3 (el) |
RS (1) | RS59369B1 (el) |
SI (1) | SI2714071T1 (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012159754A2 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
EP3473267B1 (en) | 2011-05-24 | 2021-09-08 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
EP3881324A1 (en) * | 2018-11-15 | 2021-09-22 | Nouscom AG | Selection of cancer mutations for generation of a personalized cancer vaccine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
AU1774299A (en) | 1997-12-24 | 1999-07-19 | Imperial Cancer Research Technology Limited | Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment |
ES2330078T3 (es) * | 1999-09-16 | 2009-12-04 | Eisai Corporation Of North America | Acidos nucleicos que codifican polipeptidos poliepitope. |
ATE456959T1 (de) | 2001-06-05 | 2010-02-15 | Curevac Gmbh | Stabilisierte tumorantigen-mrna mit erhöhtem g/c- gehalt |
CA2467397A1 (en) * | 2001-11-26 | 2003-06-05 | The University Of Queensland | Flavivirus vaccine delivery system |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AU2003235707A1 (en) | 2002-01-18 | 2003-07-30 | Curevac Gmbh | Immunogenic preparations and vaccines on the basis of mrna |
DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
IL158140A0 (en) | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
JP5948319B2 (ja) | 2010-05-14 | 2016-07-06 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
EP3473267B1 (en) | 2011-05-24 | 2021-09-08 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
-
2012
- 2012-05-23 EP EP18199105.0A patent/EP3473267B1/en active Active
- 2012-05-23 EP EP23169466.2A patent/EP4223311A1/en active Pending
- 2012-05-23 DK DK18199105.0T patent/DK3473267T3/da active
- 2012-05-23 PL PL18199105T patent/PL3473267T3/pl unknown
- 2012-05-23 PL PL12723117T patent/PL2714071T3/pl unknown
- 2012-05-23 EP EP21168360.2A patent/EP3892295B1/en active Active
- 2012-05-23 ME MEP-2019-237A patent/ME03498B/me unknown
- 2012-05-23 EP EP12723117.3A patent/EP2714071B1/en active Active
- 2012-05-23 RS RSP20191210 patent/RS59369B1/sr unknown
- 2012-05-23 SI SI201231660T patent/SI2714071T1/sl unknown
-
2019
- 2019-08-27 HR HRP20191535 patent/HRP20191535T1/hr unknown
- 2019-09-18 CY CY20191100986T patent/CY1122110T1/el unknown
-
2021
- 2021-11-02 CY CY20211100945T patent/CY1124685T1/el unknown
-
2023
- 2023-05-25 CY CY20231100248T patent/CY1126128T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL3473267T3 (pl) | 2022-01-10 |
CY1122110T1 (el) | 2020-11-25 |
ME03498B (me) | 2020-04-20 |
EP3892295A1 (en) | 2021-10-13 |
DK3473267T3 (da) | 2021-10-18 |
RS59369B1 (sr) | 2019-11-29 |
EP3473267A1 (en) | 2019-04-24 |
EP3473267B1 (en) | 2021-09-08 |
EP4223311A1 (en) | 2023-08-09 |
EP2714071A2 (en) | 2014-04-09 |
EP2714071B1 (en) | 2019-07-10 |
CY1126128T1 (el) | 2023-11-15 |
EP3892295B1 (en) | 2023-04-26 |
PL2714071T3 (pl) | 2019-12-31 |
HRP20191535T1 (hr) | 2019-11-29 |
SI2714071T1 (sl) | 2019-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011767A (es) | Vacunas individualizadas para el cancer. | |
CY1124685T1 (el) | Εξατομικευμενα εμβολια για τον καρκινο | |
CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
CY1124558T1 (el) | Προβλεψη επιτοπων τ κυτταρων χρησιμων για εμβολιασμο | |
CY1125084T1 (el) | Εμβολια νουκλεϊκου οξεος | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1123769T1 (el) | Νουκλεϊκα οξεα για την αγωγη αλλεργιων | |
CY1122005T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
CY1119925T1 (el) | Aνti-cd40 αντισωματα, χρησεις και μεθοδοι | |
CY1118899T1 (el) | Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων | |
CY1124028T1 (el) | Συνθεσεις και μεθοδοι για τα αντισωματα που στοχευουν την ερο | |
CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
CY1122453T1 (el) | Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc | |
MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
CY1119173T1 (el) | Νεα μορια αναστολεα jnk | |
IN2014KN00920A (el) | ||
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
CY1122850T1 (el) | Υπερδιακλαδισμενος πολυ (βητα-αμινοεστερας) για γονιδιακη θεραπεια | |
CY1121550T1 (el) | Ενωσεις πυριδινης πλαδιενολιδης και μεθοδοι χρησης | |
CY1123743T1 (el) | Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου | |
CY1123405T1 (el) | Κυτταρα θηλαστικου που εκφραζουν αντιγονα κυτταρομεγαλοϊου |